Wilson, D;
Ambler, G;
Shakeshaft, C;
Banerjee, G;
Charidimou, A;
Seiffge, D;
White, M;
... CROMIS-2 collaborators, .; + view all
(2019)
Potential missed opportunities to prevent ischaemic stroke: prospective multicentre cohort study of atrial fibrillation-associated ischaemic stroke and TIA.
BMJ Open
, 9
(7)
, Article e028387. 10.1136/bmjopen-2018-028387.
Preview |
Text
Banerjee_Potential missed opportunities to prevent ischaemic stroke. Prospective multicentre cohort study of atrial fibrillation-associated ischaemic stroke and TIA_VoR.pdf - Published Version Download (322kB) | Preview |
Abstract
OBJECTIVE: We report on: (1) the proportion of patients with known atrial fibrillation (AF); and (2) demographic, clinical or radiological differences between patients with known AF (and not treated) and patients with newly diagnosed AF, in a cohort of patients who presented with ischaemic stroke or transient ischaemic attack (TIA) not previously treated with anticoagulation. DESIGN: We reviewed cross-sectional baseline demographic and clinical data from a prospective observational cohort study, (CROMIS-2). SETTING: Patients were recruited from 79 hospital stroke centres throughout the UK and one centre in the Netherlands. PARTICIPANTS: Patients were eligible if they were adults who presented with ischaemic stroke or TIA and AF and had not been previously treated with oral anticoagulation. MAIN OUTCOME MEASURES: Proportion of patients with known AF before index ischaemic stroke or TIA from a cohort of patients who have not been previously treated with oral anticoagulation. Secondary analysis includes the comparison of CHA_{2}DS_{2}-VASc and HAS-BLED scores and other demographics and risk factors between those with newly diagnosed AF and those with previously known AF. RESULTS: Of 1470 patients included in the analysis (mean age 76 years (SD 10)), 622 (42%) were female; 999 (68%) patients had newly diagnosed AF and 471 (32%) patients had known AF. Of the 471 patients with known AF, 68% had a strong indication for anticoagulation and 89% should have been considered for anticoagulation based upon CHA_{2}DS_{2}-VASc score. Patients with known AF were more likely to have a prior history of dementia (4% vs 2%, p=0.02) and had higher HAS-BLED scores (median 3 vs 2). CHA_{2}DS_{2} -VASc, other risk factors and demographics were similar. CONCLUSIONS: About 1/3 of patients who present with stroke and have AF who have not been treated with oral anticoagulation have previously known AF. Of these patients, at least 68% were not adequately treated with oral anticoagulation. TRIAL REGISTRATION NUMBER: NCT02513316.
Archive Staff Only
 |
View Item |
